Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib ribociclib plus hormonal therapy in pre- and postmenopausal women with HR+ HER2- advanced breast cancer
jRCT2080222714Phase 1Completed
- Sponsor
- Novartis
- Start
- Jan 2015
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of ribociclib in breast cancer (4 arms), sponsored by Novartis. Started Jan 2015; status: completed.
02
Drugs
ribociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCT2080222714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222714.